BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Motixafortide readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Motixafortide\, from ClinicalTrials.gov e
 stimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT07101445-3051@assetmemo.bio
DTSTAMP:20261121T005837Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Motixafortide: Phase 4 readout est. (NCT07101445)
DESCRIPTION:Motixafortide\, phase 4\, Multiple Myeloma.\nStudy: Evaluating 
 Premedication Regimens (Methylprednisolone vs Dexamethasone-based) for the
  Prevention of Systemic and Injection Site Reactions to Motixafortide in P
 atients With Multiple Myeloma Undergoing Stem Cell Mobilization\, PARADE T
 rial\nEstimated primary completion: 31 December 2026. This is a ClinicalTr
 ials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug 
 page: https://assetmemo.bio/drug/motixafortide#upcoming-events\nRegistry r
 ecord: https://clinicaltrials.gov/study/NCT07101445
URL:https://assetmemo.bio/drug/motixafortide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06442761-3051@assetmemo.bio
DTSTAMP:20261121T005837Z
DTSTART;VALUE=DATE:20280131
DTEND;VALUE=DATE:20280201
SUMMARY:Motixafortide: Phase 1 readout est. (NCT06442761)
DESCRIPTION:Motixafortide\, phase 1.\nStudy: SCD Stem Cell Mobilization and
  Apheresis Using Motixafortide\nEstimated primary completion: January 2028
 . This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, a
 nd it can move.\nDrug page: https://assetmemo.bio/drug/motixafortide#upcom
 ing-events\nRegistry record: https://clinicaltrials.gov/study/NCT06442761
URL:https://assetmemo.bio/drug/motixafortide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04543071-3051@assetmemo.bio
DTSTAMP:20261121T005837Z
DTSTART;VALUE=DATE:20280630
DTEND;VALUE=DATE:20280701
SUMMARY:Motixafortide: Phase 2 readout est. (NCT04543071)
DESCRIPTION:Motixafortide\, phase 2\, Pancreatic Cancer.\nStudy: Chemo4METP
 ANC Combination Chemokine Inhibitor\, Immunotherapy\, and Chemotherapy in 
 Pancreatic Adenocarcinoma\nEstimated primary completion: June 2028. This i
 s a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it ca
 n move.\nDrug page: https://assetmemo.bio/drug/motixafortide#upcoming-even
 ts\nRegistry record: https://clinicaltrials.gov/study/NCT04543071
URL:https://assetmemo.bio/drug/motixafortide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07392970-3051@assetmemo.bio
DTSTAMP:20261121T005837Z
DTSTART;VALUE=DATE:20280802
DTEND;VALUE=DATE:20280803
SUMMARY:Motixafortide: Phase 2 readout est. (NCT07392970)
DESCRIPTION:Motixafortide\, phase 2.\nStudy: Motixafortide for MRD Sensitiz
 ation in AML\nEstimated primary completion: 2 August 2028. This is a Clini
 calTrials.gov estimate\, not a confirmed readout date\, and it can move.\n
 Drug page: https://assetmemo.bio/drug/motixafortide#upcoming-events\nRegis
 try record: https://clinicaltrials.gov/study/NCT07392970
URL:https://assetmemo.bio/drug/motixafortide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06506461-3051@assetmemo.bio
DTSTAMP:20261121T005837Z
DTSTART;VALUE=DATE:20291231
DTEND;VALUE=DATE:20300101
SUMMARY:Motixafortide: Phase 1 readout est. (NCT06506461)
DESCRIPTION:Motixafortide\, phase 1.\nStudy: Gene Editing For Sickle Cell D
 isease\nEstimated primary completion: December 2029. This is a ClinicalTri
 als.gov estimate\, not a confirmed readout date\, and it can move.\nDrug p
 age: https://assetmemo.bio/drug/motixafortide#upcoming-events\nRegistry re
 cord: https://clinicaltrials.gov/study/NCT06506461
URL:https://assetmemo.bio/drug/motixafortide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
